TARRYTOWN, N.Y. and SAN FRANCISCO, Jan. 30, 2014 -- Progenics Pharmaceuticals, Inc. , an oncology company focused on the development of innovative approaches to targeting and treating prostate cancer, announced that findings from a Phase 2 study of its PSMA targeted imaging agent, 1404, entitled A Phase 2 Study of 99mTc-Trofolostat SPECT/CT to ... (more)
http://ift.tt/1kf564u
http://ift.tt/1kf564u
No comments:
Post a Comment